Zealand Pharma

Zealand Pharma sought to establish a robust Double Materiality Assessment that could serve both as the analytical foundation for compliance and upcoming CSRD reporting and as a strategic tool to inform its ESG direction. The aim was to ensure cross-organisational alignment, engage senior leadership, and use the DMA process to guide the development of an updated, actionable ESG strategy.

Working closely with the finance, strategy, and sustainability teams, we facilitated a CSRD-compliant DMA process grounded in stakeholder interviews and engagement with corporate management. The assessment identified material impacts, risks, and opportunities across environmental, social, and governance topics, aligned with CSRD requirements while tailored to Zealand Pharma’s unique context as a biotech innovator.

Building on this foundation, we co-developed an updated ESG strategy structured around three core pillars: Patients, People, and Operations. Each pillar was translated into clear initiatives, measurable targets, and linked CSRD datapoints, ensuring both strategic relevance and reporting readiness.

We also helped map internal ownership by connecting each pillar with relevant data owners and operational leads to embed sustainability across the organisation.

Our collaboration enabled Zealand Pharma to move from regulatory preparation to strategic integration, delivering a CSRD-ready Double Materiality Assessment and a refreshed ESG strategy rooted in business priorities.

The result: an ESG roadmap that is both compliant and value-generating, with clear internal ownership and a structure that connects Zealand Pharma’s mission to the company’s sustainability performance as a whole.